Bone Biologics Corp

Bone Biologics Corp. announced its Annual Meeting of Stockholders will take place on August 11, 2026, at its corporate headquarters. Stockholders of record as of June 12, 2026, are invited to vote on the election of four directors, an advisory resolution on executive compensation, and the ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Proxy materials were made available to stockholders on or about July 2, 2026.

Bone Biologics Corp reported a net loss of $0.77 million for the first quarter of 2026, a significant improvement from the $1.02 million net loss in the prior year. The company's cash balance stood at $4.53 million as of March 31, 2026, which is expected to fund operations into the fourth quarter of 2026. The company continues to face substantial doubt about its ability to continue as a going concern and plans to seek additional financing. Research and development expenses decreased by 66.6% year-over-year.